Real-World Safety and Efficacy of Nivolumab in Advanced Squamous and Nonsquamous Non-Small-Cell Lung Cancer: A Retrospective Cohort Study in Croatia, Hungary, and Malta
المؤلفون المشاركون
Vrdoljak, Eduard
Jakopović, Marko
Geczi, Lajos
Bogos, Krisztina
Bošković, Lidija
Magri, Claude
Bitar, Lela
Bajić, Žarko
Samaržija, Miroslav
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-12-08
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Background.
There is a lack of real-world data on the safety and efficacy of nivolumab in patients with previously treated advanced non-small-cell lung cancer (NSCLC) especially in South East Europe, a region with particularly high incidence and an unfavorable mortality-to-incidence ratio for lung cancer.
Objectives.
To evaluate the real-world safety and efficacy of nivolumab in patients with previously treated advanced squamous and nonsquamous NSCLC in South East Europe.
Methods.
This is a multicenter, retrospective cohort study on patients with stage IIIB or IV disease with at least one previous systemic treatment who received nivolumab through an expanded-access program between 2015 and 2017 in Croatia, Malta, and Hungary.
The primary endpoint was the proportion of patients whose therapy was discontinued because of toxicity.
Secondary endpoints were the incidence of adverse events (AEs), objective response rate (ORR), disease control rate (DCR), time to response (TTR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS).
Results.
We analyzed data on 239 patients with a median (IQR) age of 62 (57–68), and 33% of them were women.
Treatment was discontinued because of toxicity in 11.6% (95% CI 7.8% to 16.5%) of patients.
The PFS was 6.4 (95% CI 5.2 to 8.6) months, and the median OS was 14.1 (10.6 to 18.0) months.
Conclusions.
The safety and efficacy of nivolumab in previously treated patients with advanced NSCLC in the real-world South East Europe clinical settings were consistent with the results of randomized clinical trials and comparable to the results from other countries.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Vrdoljak, Eduard& Jakopović, Marko& Geczi, Lajos& Bogos, Krisztina& Bošković, Lidija& Magri, Claude…[et al.]. 2020. Real-World Safety and Efficacy of Nivolumab in Advanced Squamous and Nonsquamous Non-Small-Cell Lung Cancer: A Retrospective Cohort Study in Croatia, Hungary, and Malta. Journal of Oncology،Vol. 2020, no. 2020, pp.1-9.
https://search.emarefa.net/detail/BIM-1189179
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Vrdoljak, Eduard…[et al.]. Real-World Safety and Efficacy of Nivolumab in Advanced Squamous and Nonsquamous Non-Small-Cell Lung Cancer: A Retrospective Cohort Study in Croatia, Hungary, and Malta. Journal of Oncology No. 2020 (2020), pp.1-9.
https://search.emarefa.net/detail/BIM-1189179
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Vrdoljak, Eduard& Jakopović, Marko& Geczi, Lajos& Bogos, Krisztina& Bošković, Lidija& Magri, Claude…[et al.]. Real-World Safety and Efficacy of Nivolumab in Advanced Squamous and Nonsquamous Non-Small-Cell Lung Cancer: A Retrospective Cohort Study in Croatia, Hungary, and Malta. Journal of Oncology. 2020. Vol. 2020, no. 2020, pp.1-9.
https://search.emarefa.net/detail/BIM-1189179
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1189179
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر